Mark Oki
Director of Finance/CFO at AYTU BIOPHARMA, INC.
Net worth: 28 880 $ as of 2024-03-30
Profile
Mark K.
Oki is currently the Chief Financial Officer at Neos Therapeutics, Inc. and the Chief Financial Officer, Secretary & Treasurer at Aytu Biopharma, Inc. He previously worked as an Assistant Controller at Incyte Corp.
from 1998 to 2001, Controller at Pharmacyclics LLC in 2006, CFO, Secretary & Senior VP-Finance at Alexza Pharmaceuticals, Inc. from 2006 to 2015, and Chief Financial & Accounting Officer at VIVUS, Inc. from 2015 to 2019.
Mr. Oki obtained his undergraduate degree from San Jose State University in 1991.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
AYTU BIOPHARMA, INC.
0.17% | 2023-08-10 | 9,500 ( 0.17% ) | 28 880 $ | 2024-03-30 |
Mark Oki active positions
| Companies | Position | Start |
|---|---|---|
| AYTU BIOPHARMA, INC. | Director of Finance/CFO | 2022-01-16 |
| NEOS THERAPEUTICS, INC. | Director of Finance/CFO | - |
Former positions of Mark Oki
| Companies | Position | End |
|---|---|---|
| ALEXZA PHARMACEUTICALS, INC. | Director of Finance/CFO | 2015-10-15 |
| PHARMACYCLICS, INC. | Comptroller/Controller/Auditor | 2006-03-31 |
| INCYTE CORPORATION | Corporate Officer/Principal | 2000-12-31 |
| VIVUS, INC. | Director of Finance/CFO | - |
Training of Mark Oki
| San Jose State University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| INCYTE CORPORATION | Health Technology |
| AYTU BIOPHARMA, INC. | Health Technology |
| Private companies | 4 |
|---|---|
Pharmacyclics LLC
 Pharmacyclics LLC Pharmaceuticals: MajorHealth Technology Pharmacyclics LLC engages in developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. It has product candidates in clinical development and several preclinical molecules in optimization. The company was founded by Jonathan Sessler and Richard Miller in 1991 and is headquartered in Sunnyvale, CA. | Health Technology |
VIVUS, Inc.
 VIVUS, Inc. Pharmaceuticals: MajorHealth Technology VIVUS, Inc. engaged in the development and commercialization of novel therapeutic products. The firm’s products were indicated for the treatment of obese and overweight patients, exocrine pancreatic insufficiency, and erectile dysfunction. Its products include PANCREAZE, Qsymia, and STENDRA/SPEDRA. The company was founded by Virgil A. Place in April 16, 1991 and it was headquartered in Campbell, CA. | Health Technology |
Alexza Pharmaceuticals, Inc.
 Alexza Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexza Pharmaceuticals, Inc. is a pharmaceutical company. It focused on the research, development and commercialization of novel proprietary products for the acute treatment of central nervous system conditions. Its product candidates are AZ-002 and AZ-007. The company was founded by Alejandro C. Zaffaroni in 2000 and is headquartered in Mountain View, CA. | Health Technology |
Neos Therapeutics, Inc.
 Neos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Neos Therapeutics, Inc is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Its products are Adzenys XR-ODT (amphetamine), Cotempla XR-ODT (methylphenidate), and Adzenys-ER (amphetamine) extended-release oral suspension, all for the treatment of ADHD, are the first three approved products using the Company's extended-release technology platform. The firm manufactures and markets its generic version of the branded product Tussionex, an extended-release oral suspension of hydrocodone and chlorpheniramine for the relief of cough and upper respiratory symptoms of a cold. The company was founded by Darlene R. Ryan on November 30, 1994 and is headquartered in Grand Prairie, TX. | Health Technology |
- Stock Market
- Insiders
- Mark Oki
